At the last count, there were more than seventy companies offering AI-assisted IP software solutions. Most of these companies are less than two years old.
Legal privilege ensures that you can share sensitive information with your lawyers without fear of it being used against you in court. This protection is critical in all fields of law. In patent law, without the assurance of secrecy, the ability of a patentee or a defendant to receive candid advice would be severely diminished.…
AI presents a huge dilemma for patent attorneys. There is no doubt that AI will have a dramatic impact on the profession and the business model that many firms have relied on for decades.
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.
It took a global pandemic to move some patent firms away from paper files. Today, it seems that patent attorneys are finally entering modernity with the growing adoption in the industry of automation tools for patent drafting and prosecution case management. Interestingly, much of this is being sold and promoted as “AI”, despite much of…
The comments space for the last IPKat article on claim interpretation/description amendments appears to have maxed out. Sorry everyone, but maybe it’s for the best. However, fear not, we now have a new decision to restart the debate!
G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.
We are delighted to announce that Evolve’s Claudia Greaves, has recently passed the CIPA Advanced Patent Paralegal Course (APPC). Building on her six years of patent law experience, Claudia completed intensive modules that deepen her expertise in critical areas of IP management:
The Patent Cooperation Treaty (PCT): Gaining in-depth understanding of both the International Phase…
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21?
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions.
